

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Piedmont Conference Room
To arrange public building access, please
contact Ashley Ragadio at 510.373.5731

AGENDA

ITEM	DESCRIPTION	TIME	VOTE																		
I)	<p>Call to order Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</p> <ul style="list-style-type: none"> Conflict of Interest Check/Disclosure Agenda Overview 	2 min	-																		
II)	<p>Informational Updates Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance Sanjay Bhatt, MD, Medical Director, Quality Improvement - Alameda Alliance Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</p> <ul style="list-style-type: none"> xxx 	15min	-																		
III)	<p>Review/ Approval of previous meeting minutes Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</p> <ul style="list-style-type: none"> P&T Meeting Minutes from December 11, 2018 	2 min	V																		
IV)	<p>Pharmacy Utilization Reports (Quarter 2) Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</p> <ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs <p>Consent Agenda Natalee Felten, PharmD, Pharmacist, PerformRx Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx (All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)</p>	20 min	V (on each topic)																		
	<table border="1"> <thead> <tr> <th>Monographs/Class Reviews</th> <th>Changes</th> </tr> </thead> <tbody> <tr> <td>Fluoroquinolones (oral)</td> <td> <ul style="list-style-type: none"> Minimal quantity limit and formulary alignments </td> </tr> <tr> <td>Glaucoma</td> <td> <ul style="list-style-type: none"> Minor status change of non-utilized medication for compatibility </td> </tr> <tr> <td>Respiratory Devices - Masks</td> <td> <ul style="list-style-type: none"> Minimal formulary alignment changes </td> </tr> <tr> <td>Methergine Monograph</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <th>Medication Request Guidelines</th> <th>Changes</th> </tr> <tr> <td>Inhaler Assistant Devices</td> <td> <ul style="list-style-type: none"> Minimal formulary and quantity limit alignment changes </td> </tr> <tr> <td>Makena</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <td>Off-label uses</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> </tbody> </table>	Monographs/Class Reviews	Changes	Fluoroquinolones (oral)	<ul style="list-style-type: none"> Minimal quantity limit and formulary alignments 	Glaucoma	<ul style="list-style-type: none"> Minor status change of non-utilized medication for compatibility 	Respiratory Devices - Masks	<ul style="list-style-type: none"> Minimal formulary alignment changes 	Methergine Monograph	<ul style="list-style-type: none"> No changes 	Medication Request Guidelines	Changes	Inhaler Assistant Devices	<ul style="list-style-type: none"> Minimal formulary and quantity limit alignment changes 	Makena	<ul style="list-style-type: none"> No changes 	Off-label uses	<ul style="list-style-type: none"> No changes 		
Monographs/Class Reviews	Changes																				
Fluoroquinolones (oral)	<ul style="list-style-type: none"> Minimal quantity limit and formulary alignments 																				
Glaucoma	<ul style="list-style-type: none"> Minor status change of non-utilized medication for compatibility 																				
Respiratory Devices - Masks	<ul style="list-style-type: none"> Minimal formulary alignment changes 																				
Methergine Monograph	<ul style="list-style-type: none"> No changes 																				
Medication Request Guidelines	Changes																				
Inhaler Assistant Devices	<ul style="list-style-type: none"> Minimal formulary and quantity limit alignment changes 																				
Makena	<ul style="list-style-type: none"> No changes 																				
Off-label uses	<ul style="list-style-type: none"> No changes 																				

Nuedexta	• No changes
Dronabinol	• No changes
Intranasal Steroids	• No changes
Histamine H2 Receptor Antagonists	• No changes
Memantine ER (NamendaXR)	• No changes
Multaq (dronedarone)	• No changes
Malaria prophylaxis and treatment	• No changes
Desvenlafaxine succinate (Pristiq)	• No changes
Vancomycin	• No changes
Diclofenac sodium (Solaraze) 3% gel	• No changes
Lipotropics	• No changes
Pediculicides	• No changes
Raloxifene (Evista)	• No changes
Interim Formulary changes	
• See p. XX in packet	

Pharmacy Policies & Procedures Updates

- xx

ADJOURN TO CLOSED SESSION *(Pursuant to California Government Code Title 5, §54954.5(h))*

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: September 2019 (formulary changes only; no trade secrets will be disclosed).

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx
Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx
Jeffrey Bencini, Pharmacist - Alameda Alliance

- General Medical Physician Administered Drug MRG
- Orilissa MRG

60 min

V
(on each
topic)

Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx
Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx
Jeffrey Bencini, Pharmacist - Alameda Alliance
Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

1. White Blood Cell Simulators
2. HIV Medications
3. ADHD Medication
4. Fluoroquinolones (oral)
5. Glaucoma Medications
6. Constipation and IBS: IBS-C/D, CIC, OIC
7. Chelating Agents
8. Respiratory Devices – Masks
9. Spravato
10. Methergine
11. Wound Care

RECONVENE IN OPEN SESSION

ITEM	DESCRIPTION	TIME	VOTE
VI)	Summary of Closed Session <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	2 min	-
VII)	Medication Request Guidelines <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> <i>Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx</i>	15 min	V
	<ol style="list-style-type: none"> 1. Pregabalin (Lyrica and Lyrica CR) 2. Criteria for long-acting opioids 3. Non-Formulary and PA Required Medications without Drug-Specific Criteria 4. FreeStyle Libre 5. Erythropoiesis-Stimulating Agents 6. Antiemetics 7. Inhaler Assistant Devices 8. Injectable Atypical Antipsychotic Medications 9. Anti-Obesity Medications 10. Opioid Dependency Agents 11. Injectable Methotrexate 12. Sedative Hypnotics 13. Injectable/Infusible Osteoporosis Agents 14. Injectable Bisphosphonates & Skeletal-Related Events Medications 15. Flector, Pennsaid, Diclofenac 16. Alpha-1 Proteinase Inhibitors (Human) 17. Xolair (omalizumab) 18. Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitors 19. Drugs for Gender Dysphoria For Less Than 21 Years Old 20. Drugs for Gender Dysphoria For At Least 21 Years Old 21. Cartilagenous Repair Agents 22. Makena 23. Off-label uses 24. Nuedexta (dextromethorphan/quinidine) 25. Dronabinol 26. Intranasal Steroids 27. Histamine H2 Receptor Antagonists 28. Memantine ER (Namenda XR) 29. Multaq (dronedarone) 30. Malaria prophylaxis and treatment agents 31. Desvenlafaxine succinate (Pristiq) 32. Vancomycin 33. Diclofenac sodium (Solaraze) 3% gel 34. Lipotropics 35. Pediculicides 36. Raloxifene (Evista) 		
VIII)	Interim Changes (Consent Agenda) <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> <i>Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx</i>	0 min	-

IX) Informational Updates on New Developments in Pharmacy

Natalee Felten, PharmD, Pharmacist, PerformRx

Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx

- New Product Review

5 min -

X) Public Comment

2 min -

XI) Adjournment

- P&T Committee Member Forms

- -

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS

NEXT MEETING	2019 P&T MEETINGS
December 17 th , 2019	December 17 th , 2019

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.